Insider Transactions in Q4 2022 at Heron Therapeutics, Inc. (HRTX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2022
|
Stephen Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+42.58%
|
-
|
|
Dec 16
2022
|
Sharmila Dissanaike Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+41.1%
|
-
|
|
Dec 16
2022
|
Craig A Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+42.65%
|
-
|
|
Dec 16
2022
|
Susan Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+41.1%
|
-
|
|
Dec 16
2022
|
Waage Christian Director |
BUY
Grant, award, or other acquisition
|
Direct |
38,580
+42.48%
|
-
|
|
Oct 31
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Other acquisition or disposition
|
Direct |
1,655
+7.6%
|
$4,965
$3.27 P/Share
|
|
Oct 31
2022
|
Barry D Quart Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
1,655
+1.0%
|
$4,965
$3.27 P/Share
|
|
Oct 31
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Other acquisition or disposition
|
Direct |
1,654
+6.89%
|
$4,962
$3.27 P/Share
|
|
Oct 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-8.86%
|
$6,036
$3.76 P/Share
|
|
Oct 13
2022
|
David Leslie Szekeres EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+11.59%
|
-
|
|
Oct 13
2022
|
Barry D Quart Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-3.13%
|
$15,657
$3.76 P/Share
|
|
Oct 13
2022
|
Barry D Quart Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,768
+5.58%
|
-
|
|
Oct 13
2022
|
John Poyhonen President & CCO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-4.9%
|
$6,036
$3.76 P/Share
|
|
Oct 13
2022
|
John Poyhonen President & CCO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+6.66%
|
-
|
|
Oct 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
861
-4.01%
|
$2,583
$3.76 P/Share
|
|
Oct 13
2022
|
Lisa Peraza VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,485
+5.51%
|
-
|
|
Oct 13
2022
|
Kimberly Manhard EVP, Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-9.82%
|
$6,036
$3.76 P/Share
|
|
Oct 13
2022
|
Kimberly Manhard EVP, Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,814
+12.75%
|
-
|